Therapy Areas: Oncology
BioXpedia A/S, BioSkryb Genomics Forge European Partnership
23 September 2022 - - US-based single-cell analysis molecular chemistry and technology specialist BioSkryb Genomics has forged a partnership with Denmark-based contract research laboratory BioXpedia A/S, the company said.

This partnership forms a single source, end to end solution for the evaluation of multiomics in single cells supporting unprecedented target identification and therapeutic advancement.

Multiomics efforts have taken center stage in biomedical research leading to the development of new insights into biological events and processes.

As an example, in the last decade, CRISPR gene editing has evolved as one of the most promising innovations to change how researchers study and treat disease.

This technology has already proven effective in treating a range of diseases, including cancer, liver diseases, and genetic syndromes.

As revolutionary as the Nobel-prize winning technology is, the gene editing approach is not without risk, requiring a deep and complete review of the full genome edited to minimize unintended consequences, including risk of malignancy.

This is one of many examples proving the transformative potential in understanding the multiomic picture of a single cell with substantial precision to develop and deliver successful disease management interventions.

According to Emergen Research, the global targeted therapeutics market size was ~USD94 bn in 2020 and is expected to reach USD 162bn in 2028.

BioXpedia A/S will offer the European market an unparalleled solution for novel target identification, deep understanding of multiomics relating to disease management, and quality control analysis of cells that have undergone gene editing.

This solution, utilizing BioSkryb Genomics' ResolveDNA and ResolveOME chemistries as a backbone, will enable the identification of unintended impacts on the genome, providing a reliable and accurate quality control measure for gene edited cells.

BioSkryb Genomics' ResolveDNA and ResolveOME single-cell amplification technology provides deeper insights into the whole genome and whole transcriptome in a single workflow to conduct cellular characterization.

ResolveDNA and ResolveOME incorporates proprietary primary template-directed amplification technology.

PTA employs controlled reaction parameters, allowing uniform amplification of >95% of the genomes of single cells while detecting >7,000 genes, even in low input samples, with market leading precision and sensitivity.

This approach results in the highest quality analyses available TODAY for single-cell genomic applications.

BioSkryb Genomics is a developer of genomic amplification technologies. BioSkryb Genomics engineers single-cell whole genome amplification tools to study genomic heterogeneity aiding researchers in the discovery of novel insights into human disease at the cellular level.

The company is headquartered in Durham, North Carolina.

BioXpedia A/S is a high-end bioanalytical contract research laboratory. The company provides flexible end-to-end services within genomics and proteomics to support biological and clinical research for academia, biotech, and pharma.

BioXpedia is continuously focusing on making new, groundbreaking technologies available for the research communities to enable the best analytical solutions. The company is headquartered in Aarhus, Denmark.